Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
This ESMO Clinical Practice Guidelines features recommendations for diagnosis, staging & risk assessment, treatment plan for asymptomatic patients, recommendations for treatment in first-line & relapsed disease settings, and response evaluation & follow-up.
Waldenström's macroglobulinaemia (WM) is a rare disease. It accounts for 1%–2% of haematological neoplasms with a reported age-adjusted incidence rate of 3.4 per million among males and 1.7 per million among females in the United States and 7.3 and 4.2 per million European standard population [1, 2]. WM is a disease of the elderly with a median age of 63–68 years with a male predominance.